



STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU OBTINEREA ATESTATULUI DE ABILITARE ÎN CADRUL IOSUD UMF IAȘI

Conform

1. Ordinului ministrului educației naționale și cercetării științifice nr. 6.129/2016 privind aprobarea standardelor minimale necesare și obligatorii pentru conferirea titlurilor didactice din învățământul superior
2. Metodologiei privind organizarea și desfășurarea procesului de obținere a atestatului de abilitare în IOSUD - UMF IAȘI

1. STANDARD MINIMAL ARTICOLE ISI AUTOR PRINCIPAL*

*calitatea de autor principal este atribuită pentru primul autor, ultimul autor, autorul corespondent, sau alți autori a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent

Domeniul Medicină, Farmacie: 10 articole, publicate pe parcursul întregii activități

Domeniul Medicină Dentară: 8 articole în revistă cu factor de impact >0.3, de la ultimă promovare sau ultimii 5 ani (pentru candidații care provin din afara sistemului de învățământ)

RAPORTARE ARTICOLE ISI AUTOR PRINCIPAL

(listă, cu link-urile corespunzătoare pentru verificare, active)

1. Cucuteanu B, Negru D, Gavrilăscu O, Popa IV, Floria M, **Mihai C**¹, Cijevschi Prelipcean C, Dranga M. Extrapancratic necrosis volume: A new tool in acute pancreatitis severity assessment? World J Clin Cases, 2021, 9(31): 9395-9405. [IF=1.337](https://www.wjgnet.com/2307-8960/full/v9/i31/9395.htm) (Research Areas: General & Internal Medicine)
<https://www.wjgnet.com/2307-8960/full/v9/i31/9395.htm>
standardeminimale\isi_principal\2021.WJCC.9.31.9395-9405.pdf
2. Gavril OI, Arhire LI, Gavrilăscu O, Dranga M, Barboi O, Gavril RS, Popescu R, Cijevschi Prelipcean C, Trifan AV, **Mihai C**. Role of pnp1a3 in the assessment and monitoring of hepatic steatosis and fibrosis in patients with chronic hepatitis c infection who achieved a sustained virologic response, Med Lith, 2021, 57(11): art. no 1153. [IF=2.43](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618282/pdf/medicina-57-01153.pdf) (Research Areas: General & Internal Medicine)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618282/pdf/medicina-57-01153.pdf>
standardeminimale\isi_principal\2021.ML.57.11.1153.pdf
standardeminimale\isi_principal\2021.ML.57.11.1153.WSCC.pdf

¹corresponding author

3. Dranga M, Boiculese LV, Popa IV, Floria M, Gavril OI, Barboi OB, Trifan A, CijevschiPrelipcean C, **Mihai C**², Gavrilescu O. Anemia in crohn's disease-the unseen face of inflammatory bowel disease, Med Lith, 2021, 57(10): art. no 1046. [IF=2.43](#) (Research Areas:General & Internal Medicine)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539193/pdf/medicina-57-01046.pdf>
[standardeminimale\visi_principal\2021.ML.57.10.1046.pdf](#)
[standardeminimale\visi_principal\2021.ML.57.10.1046.WSCC.pdf](#)
4. Popa IV, Burlacu A, Gavrilescu O, Dranga M, CijevschiPrelipcean C, **Mihai C**. A new approach to predict ulcerative colitis activity through standard clinical-biological parameters using a robust neural network model, Neural Comput Appl, 2021, 33(21): 14133-14146. [IF=5.606](#) (Research Areas:Computer Science)
<https://link.springer.com/content/pdf/10.1007/s00521-021-06055-x.pdf>
[standardeminimale\visi_principal\2021.NCA.33.21.14133-14146.pdf](#)
[standardeminimale\visi_principal\2021.NCA.33.21.14133-14146.WSCC.pdf](#)
5. Popa IV, Diculescu M, **Mihai C**³, CijevschiPrelipcean C, Burlacu A. Developing a neural network model for a non-invasive prediction of histologic activity in inflammatory bowel diseases, Turk J Gastroenterol, 2021, 32(3): 276-286. [IF=1.852](#) (Research Areas:Gastroenterology & Hepatology)
<https://www.turkjgastroenterol.org/en/developing-a-neural-network-model-for-a-non-invasive-prediction-of-histologic-activity-in-inflammatory-bowel-diseases-1628413>
[standardeminimale\visi_principal\2021.TJG.32.3.276-286.pdf](#)
[standardeminimale\visi_principal\2021.TJG.32.3.276-286.WSCC.pdf](#)
6. Cardoneanu A, **Mihai C**⁴, Rezus E, Burlui A, Popa I, CijevschiPrelipcean C. Gut microbiota changes in inflammatory bowel diseases and ankylosing spondylitis, J Gastrointest Liver Dis, 2021, 30(1): 46-54. [IF=2.008](#) (Research Areas: Gastroenterology & Hepatology)
<https://www.jgld.ro/jgld/index.php/jgld/article/view/2823/1666>
[standardeminimale\visi_principal\2021.JGLD.30.1.46-54.pdf](#)
[standardeminimale\visi_principal\2021.JGLD.30.1.46-54.WSCC.pdf](#)
7. Gavrilescu O, CijevschiPrelipcean C, Dranga M, Soponaru C, Mihai C. The specialized educational and psychological counseling in inflammatory bowel disease patients - a target or a challenge?, Turk J Gastroenterol, 2020, 31(11): 760-766. [IF=1.852](#) (Research Areas:Gastroenterology & Hepatology)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759224/pdf/tjg-31-11-760.pdf>
[standardeminimale\visi_principal\2020.TJG.31.11.760-766.pdf](#)
[standardeminimale\visi_principal\2020.TJG.31.11.760-766.WSCC.pdf](#)
8. Popa IV, Burlacu A, **Mihai C**⁵, CijevschiPrelipcean C. A machine learning model accurately predicts ulcerative colitis activity at one year in patients treated with anti-tumour necrosis factor alpha agents, Med Lith, 2020, 56(11): art. no 628. [IF=2.43](#) (Research Areas:General & Internal Medicine)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699478/pdf/medicina-56-00628.pdf>
[standardeminimale\visi_principal\2020.ML.56.11.628.pdf](#)
[standardeminimale\visi_principal\2020.ML.56.11.628.WSCC.pdf](#)
9. Popa IV, Diculescu M, **Mihai C**⁶, Cijevschi-Prelipcean C, Burlacu A. Covid-19 and inflammatory bowel diseases: risk assessment, shared molecular pathways, and therapeutic challenges, Gastroenterol Res Pract., 2020, art. no 1918035. [IF=2.26](#) (Research Areas:Gastroenterology & Hepatology)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352130/pdf/GRP2020-1918035.pdf>

² corresponding author

³ corresponding author

⁴ corresponding author

⁵ corresponding author

⁶ corresponding author

[standardeminimale\isi_principal\2020.GRP.1918035.pdf](#)
[standardeminimale\isi_principal\2020.GRP.1918035.WSCC.pdf](#)

10. **Mihai C**, Mihai BM, Dranga M, Cardoneanu A, Cijevschi Prelipcean C. Lactobacillus reuteri - an alternative in the first-line of helicobacter pylori eradication, Farmacia, 2019, 67(5): 871-876. [IF=1.607](#) (Research Areas: Pharmacology & Pharmacy)
https://farmaciajournal.com/wp-content/uploads/2019-05-art-17-Mihai_Mihai_Prelipceanu_871-876.pdf
[standardeminimale\isi_principal\2019.F.67.5.871-876.pdf](#)
[standardeminimale\isi_principal\2019.F.67.5.871-876.WSCC.pdf](#)
11. Dranga M, **Mihai C**⁷, Gavrilescu O, Cardoneanu A, Floria M, Mihai B, Cijevschi Prelipcean C. The role of combining biochemical markers in assessing the endoscopic activity in ulcerative colitis, Rev Chim, 2018, 69(5): 1268-1271. [IF=1.605](#) (Research Areas: Chemistry; Engineering)
<https://bch.ro/pdfRC/50%20DRANGA%205%2018.pdf>
[standardeminimale\isi_principal\2018.RC.69.5.1268-1271.pdf](#)
[standardeminimale\isi_principal\2018.RC.69.5.1268-1271.WSCC.pdf](#)
12. **Mihai C**, Cijevschi Prelipcean C, Dranga M, Gavrilescu O, Cardoneanu A, Lacatusu C, Mihai BM. Correlations between inflammatory biomarkers and activity in inflammatory bowel diseases, Rev Chim, 2018, 69(3): 710-713. [IF=1.605](#) (Research Areas: Chemistry; Engineering)
<https://bch.ro/pdfRC/38%20MIHAI%20C%203%2018.pdf>
[standardeminimale\isi_principal\2018.RC.69.3.710-713.pdf](#)
[standardeminimale\isi_principal\2018.RC.69.3.710-713.WSCC.pdf](#)
13. Cardoneanu A, Cijevschi Prelipcean C, Danciu M, **Mihai C**⁸, Dranga M, Gavrilescu O, Rezus E. Looking beyond gut inflammation in inflammatory bowel disease, Rom J MorpholEmbryol, 2018, 59(4): 1097-1105. [IF=1.5](#) (Research Areas: Developmental Biology)
<https://www.rjme.ro/RJME/resources/files/59041810971105.pdf>
[standardeminimale\isi_principal\2018.RJME.59.4.1097-1105.pdf](#)
[standardeminimale\isi_principal\2018.RJME.59.4.1097-1105.WSCC.pdf](#)
14. Mihai BM, **Mihai C**⁹, Cijevschi-Prelipcean C, Grigorescu ED, Dranga M, Drug V, Sporea I, Lacatusu CM. Bidirectional relationship between gastric emptying and plasma glucose control in normoglycemic individuals and diabetic patients, J. Diabetes Res., 2018, art. no 1736959. [IF=3.04](#) (Research Areas: Endocrinology & Metabolism; Research & Experimental Medicine)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192082/pdf/JDR2018-1736959.pdf>
[standardeminimale\isi_principal\2018.JDR.1736959.pdf](#)
[standardeminimale\isi_principal\2018.JDR.1736959.WSCC.pdf](#)
15. **Mihai C**, Mihai B, Trifan A, Stanciu C, Gheorghe L, Diculescu M, Curescu M, Brisc C, Goldis A, Bataga S, Sandulescu L, Rogoveanu I, Seicean A, Cijevschi Prelipcean C. Metabolic syndrome and genotype 1 virus c compensated liver cirrhosis in the era of directly acting antiviral therapy, Hepat Mon, 2017, 17(7): art. no e58022. [IF=1.81](#) (Research Areas: Gastroenterology & Hepatology)
<https://sites.kowsarpub.com/hepatmon/articles/58022.html>
[standardeminimale\isi_principal\2017.HM.17.7.e58022.pdf](#)
[standardeminimale\isi_principal\2017.HM.17.7.e58022.WSCC.pdf](#)
16. Palaghia M, **Mihai C**¹⁰, Lozneau L, Ciobanu D, Trofin AM, Rotariu A, Tarcoveanu F, Cijevschi

⁷ corresponding author

⁸ corresponding author

⁹ corresponding author

¹⁰ corresponding author

Prelipcean C. E-cadherin expression in primary colorectal cancer and metastatic lymph nodes, Rom J MorpholEmbryol, 2016, 57(1): 205-209. [IF=0.67](#) (Research Areas:Developmental Biology)
<https://www.rjme.ro/RJME/resources/files/570116205209.pdf>
[standardeminimale\isi_principal\2016.RJME.57.1.205-209.pdf](#)
[standardeminimale\isi_principal\2016.RJME.57.1.205-209.WSCC.pdf](#)

17. **Mihai C**, Stefanescu G, Gogalniceanu P, Anton C, Dranga M, Jigararu O, Balmus IM, Timofte D, Ciobica A, Cijevschi Prelipcean C. Specific features of *Clostridium difficile* colitis in patients with inflammatory bowel disease, Arch BiolSci, 2015, 67(1): 147-153. [IF=0.367](#) (Research Areas:Life Sciences & Biomedicine - Other Topics)
<http://doiserbia.nb.rs/img/doi/0354-4664/2015/0354-46641400017M.pdf>
[standardeminimale\isi_principal\2015.ABS.67.1.147-153.pdf](#)
[standardeminimale\isi_principal\2015.ABS.67.1.147-153.WSCC.pdf](#)

2. STANDARD MINIMALARTICOLE ISI COAUTOR

DomeniulMedicină, Farmacie: 5 articole, publicatepeparcursulîntregiiaactivităţi

RAPORTAREARTICOLE ISI COAUTOR

(listă, cu link-urilecorespunzătoarepentruverificare, active)

1. Trifan A, Stanciu C, Iliescu L, Sporea I, Baroiu L, Diculescu M, Luca MC, Miftode E, Cijevschi C, **Mihai C**, Sparchez ZA, Pojoga C, Streinu-Cercel A, Gheorghe L. Effectiveness of 8-and 12-week treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve hcv patients in a real-life setting in Romania: the amethyst study, J Gastrointest Liver Dis, 2021, 30(1): 88-93. [IF=2.008](#) (Research Areas: Gastroenterology & Hepatology)
<https://www.jgld.ro/jgld/index.php/jgld/article/view/3373/1691>
[standardeminimale\isicoautor\2021.JGLD.30.1.88-93.pdf](#)
[standardeminimale\isicoautor\2021.JGLD.30.1.88-93.WSCC.pdf](#)
2. Sirli R, Sporea I, Popescu A, Danila M, Sandulescu DL, Saftoiu A, Moga T, Sparchez Z, Cijevschi C, **Mihai C**, Ioanitescu S, Nedelcu D, Iacob N, Miclaus G, Brisc C, Badea R. Contrast-enhanced ultrasound for the assessment of focal nodular hyperplasia - results of a multicentre study, Med Ultrason, 2021, 23(2): 140-146. [IF=1.611](#) (Research Areas:Acoustics; Radiology, Nuclear Medicine & Medical Imaging)
<https://www.medultrason.ro/medultrason/index.php/medultrason/article/view/2912>
[standardeminimale\isicoautor\2021.MU.23.2.140-146.pdf](#)
[standardeminimale\isicoautor\2021.MU.23.2.140-146.WSCC.pdf](#)
3. Rotaru TS, Fratila OC, Barboi O, Ciortescu I, **Mihai C**, Anton C, Stefanescu G, Drug V. A comparison using standardized measures for patients with irritable bowel syndrome: trust in the gastroenterologist and reliance on the internet, NeurogastroenterolMotil, 2021, 33(5): art. no e13977. [IF=3.598](#) (Research Areas:Gastroenterology & Hepatology; Neurosciences & Neurology)
<https://onlinelibrary.wiley.com/doi/10.1111/nmo.13977>
[standarde_minimale\isi_coautor\2021.NGM.33.5.e13977.pdf](#)
[standardeminimale\isicoautor\2021.NGM.33.5.e13977.WSCC.pdf](#)
4. Sporea I, Sandulescu DL, Sirli R, Popescu A, Danila M, Sparchez Z, **Mihai C**, Ioanitescu S, Moga T, Timar B, Brisc C, Nedelcu D, Saftoiu A, Enachescu V, Badea R. Contrast-enhanced ultrasound for the characterization of malignant versus benign focal liver lesions in a prospective multicenter experience - the srumb study, J Gastrointest Liver Dis, 2019, 28(2): 191-196. [IF=2.351](#) (Research Areas: Gastroenterology & Hepatology)
<https://www.jgld.ro/jgld/index.php/jgld/article/view/180/120>
[standardeminimale\isicoautor\2019.JGLD.28.2.191-196.pdf](#)

[standardeminimale\isicoautor\2019.JGLD.28.2.191-196.WSCC.pdf](#)

5. Danciu M, Alexa-Stratulat T, Stefanescu C, Dodi G, Tamba BI, Mihai CT, Stanciu GD, Luca A, Spiridon IA, Ungureanu LB, Ianole V, Ciortescu I, **Mihai C**, Stefanescu G, Chirila I, Ciobanu R, Drug VL. Terahertz spectroscopy and imaging: a cutting-edge method for diagnosing digestive cancers, Materials, 2019, 12(9): art. no 1519. [IF=3.057](#) (Research Areas:Chemistry; Materials Science; Metallurgy & Metallurgical Engineering; Physics)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539301/pdf/materials-12-01519.pdf>
[standardeminimale\isicoautor\2019.MA.12.9.1519.pdf](#)
[standardeminimale\isicoautor\2019.MA.12.9.1519.WSCC.pdf](#)
6. Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, **Mihai C**, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of hcv genotype 1b compensated cirrhosis in patients aged 70 years or older, Medicine (Baltimore), 2017, 96(50): art. no e9271. [IF=2.028](#) (Research Areas:General & Internal Medicine)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815789/pdf/medi-96-e9271.pdf>
[standardeminimale\isicoautor\2017.ME.96.50.e9271.pdf](#)
[standardeminimale\isicoautor\2017.ME.96.50.e9271.WSCC.pdf](#)
7. Badea MA, Drug VL, Dranga M, Gavrilescu O, Stefanescu G, Popa I, **Mihai C**, Cijevschi-Prelipcean C. Diagnosis of minimal hepatic encephalopathy in a tertiary care center from Eastern Romania: validation of the psychometric hepatic encephalopathy score (phes), Metab Brain Dis, 2016, 31(6 sp. SI): 1463-1471. [IF=2.297](#) (Research Areas:Endocrinology & Metabolism; Neurosciences & Neurology)
<https://link.springer.com/content/pdf/10.1007/s11011-016-9878-y.pdf>
[standardeminimale\isicoautor\2016.MBD.31.6.1463-1471.pdf](#)
[standardeminimale\isicoautor\2016.MBD.31.6.1463-1471.WSCC.pdf](#)
8. Dranga M, **Mihai C**, Drug V, Dumitrescu G, Cijevschi Prelipcean C. A rapid test for assessing disease activity in ulcerative colitis, Turk J Gastroenterol, 2016, 27(2): 149-155. [IF=1.852](#) (Research Areas:Gastroenterology & Hepatology)
<https://www.turkjgastroenterol.org/en/a-rapid-test-for-assessing-disease-activity-in-ulcerative-colitis-1625130>
[standardeminimale\isicoautor\2016.TJG.27.2.149-155.pdf](#)
[standardeminimale\isicoautor\2016.TJG.27.2.149-155.WSCC.pdf](#)
9. Gavrilescu O, **Mihai C**, Anton-Paduraru DT, Moisa S, Ciubara A, Cijevschi-Prelipcean C. Impact of inflammatory bowel diseases on quality of life, Rev CercetIntervSoc, 2015, 50: 80-95. [IF=0.424](#) (Research Areas:Social Sciences - Other Topics)
https://www.rcis.ro/images/documente/rcis50_06.pdf
[standardeminimale\isicoautor\2015.RCIS.50.80-95.pdf](#)
[standardeminimale\isicoautor\2015.RCIS.50.80-95.WSCC.pdf](#)
10. Sporea I, Badea R, Popescu A, Sparchez Z, Sirli RL, Danila M, Sandulescu L, Bota S, Calescu DP, Nedelcu D, Brisc C, Ciobaca L, Gheorghe L, Socaciu M, Martie A, Ioanitescu S, Tamas A, Streba CT, Iordache M, Simionov I, Jinga M, Anghel A, Cijevschi Prelipcean C, **Mihai C**, Stanciu SM, Stoicescu D, Dumitru E, Pietrareanu C, Bartos D, Saplacan RM, Parvulescu I, Vadan R, Smira G, Tuta L, Saftoiu A. Contrast-enhanced ultrasound (ceus) for the evaluation of focal liver lesions - a prospective multicenter study of its usefulness in clinical practice, Ultrascall Med, 2014, 35(3): 259-266. [IF=4.924](#) (Research Areas:Acoustics; Radiology, Nuclear Medicine & Medical Imaging)

<https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0033-1355728>
[standardeminimale\isicoautor\2014.UM.35.3.259-266.pdf](#)
[standardeminimale\isicoautor\2014.UM.35.3.259-266.WSCC.pdf](#)

11. Dumitrescu G, **Mihai C**, Dranga M, Cijevschi Prelipcean C. Serum 25-hydroxyvitamin d concentration and inflammatory bowel disease characteristics in Romania, World J Gastroenterol, 2014, 20(9): 2392-2396. [IF=2.369](#) (Research Areas:Gastroenterology & Hepatology)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942843/pdf/WJG-20-2392.pdf>
[standardeminimale\isicoautor\2014.WJG.20.9.2392-2396.pdf](#)
[standardeminimale\isicoautor\2014.WJG.20.9.2392-2396.WSCC.pdf](#)
12. Cijevschi Prelipcean C, **Mihai C**, Gogalniceanu P, Anton C, Anton E. Current aspects with regard to the link between pregnancy and inflammatory bowel disease, Arch BiolSci, 2014, 66(3): 1047-1054. [IF=0.718](#) (Research Areas:Life Sciences & Biomedicine - Other Topics)
<http://www.doiserbia.nb.rs/img/doi/0354-4664/2014/0354-46641403047P.pdf>
[standardeminimale\isicoautor\2014.ABS.66.3.1047-1054.pdf](#)
[standardeminimale\isicoautor\2014.ABS.66.3.1047-1054.WSCC.pdf](#)
13. Lacatusu C, Cijevschi-Prelipcean C, **Mihai C**, Mihai B. Ethics of artificial nutrition, Rev Rom Bioet, 2014, 12(1): 44-55. [IF=0.462](#) (Research Areas:Social Sciences - Other Topics; Medical Ethics; Biomedical Social Sciences)
<https://www.proquest.com/docview/1522764938/>
[standardeminimale\isicoautor\2014.RRB.12.1.44-55.pdf](#)
[standardeminimale\isicoautor\2014.RRB.12.1.44-55.WSCC.pdf](#)
14. Jigararu AO, Nedelciuc O, Blaj A, Badea M, **Mihai C**, Diculescu M, Cijevschi-Prelipcean C. Is rifaximin effective in maintaining remission in crohn's disease? Dig Dis, 2014, 32(4): 378-383. [IF=2.181](#) (Research Areas:Gastroenterology & Hepatology)
https://docksci.com/is-rifaximin-effective-in-maintaining-remission-in-crohns-disease_5ad0a540d64ab219b570d3dd.html
[standardeminimale\isicoautor\2014.DD.32.4.378-383.pdf](#)
[standardeminimale\isicoautor\2014.DD.32.4.378-383.WSCC.pdf](#)
15. Sporea I, Popescu A, Focsa M, Becheanu G, Sirli R, Cornianu M, Gheorghe L, Cijevschi Prelipcean C, **Mihai C**, Rogoveanu I, Sandulescu L. Do the needle type and the operator experience influence liver biopsy specimen quality?, Cent Eur J Med, 2013, 8(5): 669-673. [IF=0.209](#) (Research Areas:General & Internal Medicine)
<https://www.degruyter.com/document/doi/10.2478/s11536-012-0148-z/html>
[standardeminimale\isicoautor\2013.CEJM.8.5.669-673.pdf](#)
[standardeminimale\isicoautor\2013.CEJM.8.5.669-673.WSCC.pdf](#)
16. Chirila I, Petrariu FD, Ciortescu I, **Mihai C**, Drug VL. Diet and irritable bowel syndrome, J. Gastrointest. Liver Dis., 2012, 21(4): 357-362. [IF=1.855](#) (Research Areas: Gastroenterology &Hepatology)
<https://www.jgld.ro/jgld/index.php/jgld/article/view/2012.4.7/771>
[standardeminimale\isicoautor\2012.JGLD.21.4.357-362.pdf](#)
[standardeminimale\isicoautor\2012.JGLD.21.4.357-362.WSCC.pdf](#)
17. Drug V, Haliga R, Akbar Q, **Mihai C**, Cijevschi Prelipcean C, Stanciu C. Ascites with stronglylodesstercoralis in a patient with acute alcoholic pancreatitis and liver cirrhosis, J Gastrointest Liver Dis, 2009, 18(3): 367-369. [IF=1.265](#) (Research Areas: Gastroenterology & Hepatology)
<https://www.jgld.ro/jgld/index.php/jgld/article/view/2009.3.17/1065>

[standardeminimale\isicoautor\2009.JGLD.18.3.367-369.pdf](#)
[standardeminimale\isicoautor\2009.JGLD.18.3.367-369.WSCC.pdf](#)

3. STANDARD MINIMALFACTOR CUMULAT DE IMPACT*

*se calculeazăca sumă a factorilor de impact a revistelorîncare au fostpublicatearticoleleîncalitate de autor principal, înanulaparițieiarticolului

DomeniulMedicină, Farmacie: 10, pe parcursulîntregiiaactivității

DomeniulMedicinăDentară: 2.4, de la ultimapromovare sauultimii 5 ani (pentrucandidații care provin dinafarasistemului de învățământ)

RAPORTAREFACTOR CUMULAT DE IMPACT

(cifră, calculată conform indicațiilor, cu link-urilecorespunzătoarepentruverificare, active)

34.409

$(\underline{1.337} + \underline{2.43} + \underline{2.43} + \underline{5.606} + \underline{1.852} + \underline{2.008} + \underline{1.852} + \underline{2.43} + \underline{2.26} + \underline{1.607} + \underline{1.605} + \underline{1.605} + \underline{1.5} + \underline{3.04} + \underline{1.81} + \underline{0.67} + \underline{0.367})$

4. STANDARD MINIMAL INDICE HIRSCH*

DomeniulMedicină, MedicinăDentară, Farmacie = 6

*conform ISI Web of Science, Core Collection, Thomson Reuters

RAPORTARE INDICE HIRSCH

(cifră, cu link-urilecorespunzătoarepentruverificare, active)

10

[standardeminimale\h-index WSCC.pdf](#)

5. STANDARD MINIMAL ARTICOLE BDI*

DomeniulMedicinăDentară: 20 articole de la ultimapromovare, încalitate de autor principal

*echivalare = 1 articol ISIautor principal =3 articole BDI autor principal, dar nu invers

RAPORTARE ARTICOLE BDI

(listă, cu link-urilecorespunzătoarepentruverificare, active)

Nu este cazul

Data,
21.01.2022

Conf. univ. dr. Mihai Cătălina

